Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy.

ABSTRACT:

Background

Subclonal evolution during primary breast cancer treatment is largely unexplored. We aimed to assess the dynamic changes in subclonal composition of treatment-naïve breast cancers during neoadjuvant chemotherapy.

Methods

We performed whole exome sequencing of tumor biopsies collected before, at therapy switch, and after treatment with sequential epirubicin and docetaxel monotherapy in 51 out of 109 patients with primary breast cancer, who were included in a prospectively registered, neoadjuvant single-arm phase II trial.

Results

There was a profound and differential redistribution of subclones during epirubicin and docetaxel treatment, regardless of therapy response. While truncal mutations and main subclones persisted, smaller subclones frequently appeared

SUBMITTER: Venizelos A 

PROVIDER: S-EPMC9367103 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature